Cargando…

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injec...

Descripción completa

Detalles Bibliográficos
Autores principales: Álvarez-Guisasola, Fernando, Orozco-Beltrán, Domingo, Cebrián-Cuenca, Ana M., Ruiz Quintero, Manuel Antonio, Angullo Martínez, Escarlata, Ávila Lachica, Luis, Ortega Millán, Carlos, Caride Miana, Elena, Navarro-Pérez, Jorge, Sagredo Perez, Julio, Barrot de la Puente, Joan, Cos Claramunt, Francesc Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836897/
https://www.ncbi.nlm.nih.gov/pubmed/31320123
http://dx.doi.org/10.1016/j.aprim.2019.05.014
Descripción
Sumario:Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.